We Are One Seven LLC purchased a new stake in Integra Lifesciences Holdings Corp (NASDAQ:IART) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 3,218 shares of the life sciences company’s stock, valued at approximately $211,000.
Other large investors also recently made changes to their positions in the company. Zeke Capital Advisors LLC bought a new stake in Integra Lifesciences in the second quarter valued at $204,000. Eagle Boston Investment Management Inc. bought a new stake in Integra Lifesciences in the second quarter valued at $223,000. Hsbc Holdings PLC bought a new stake in Integra Lifesciences in the first quarter valued at $235,000. World Asset Management Inc bought a new stake in Integra Lifesciences in the second quarter valued at $261,000. Finally, LS Investment Advisors LLC grew its position in Integra Lifesciences by 99.3% in the second quarter. LS Investment Advisors LLC now owns 4,276 shares of the life sciences company’s stock valued at $275,000 after acquiring an additional 2,130 shares during the period. Hedge funds and other institutional investors own 84.41% of the company’s stock.
Integra Lifesciences stock opened at $61.96 on Monday. The company has a current ratio of 3.52, a quick ratio of 2.27 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of 31.94, a price-to-earnings-growth ratio of 2.03 and a beta of 0.57. Integra Lifesciences Holdings Corp has a 52 week low of $41.51 and a 52 week high of $67.50.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 25th. The life sciences company reported $0.60 EPS for the quarter, hitting analysts’ consensus estimates of $0.60. The company had revenue of $366.20 million for the quarter, compared to analyst estimates of $368.08 million. Integra Lifesciences had a return on equity of 17.43% and a net margin of 5.10%. The business’s revenue was up 29.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.45 earnings per share. Research analysts anticipate that Integra Lifesciences Holdings Corp will post 2.4 earnings per share for the current year.
In other news, Director Stuart Essig sold 69,871 shares of the company’s stock in a transaction on Tuesday, July 24th. The stock was sold at an average price of $63.54, for a total transaction of $4,439,603.34. Following the transaction, the director now owns 1,438,367 shares of the company’s stock, valued at $91,393,839.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Glenn Coleman sold 8,916 shares of the company’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $63.00, for a total value of $561,708.00. Following the transaction, the vice president now directly owns 16,795 shares in the company, valued at approximately $1,058,085. The disclosure for this sale can be found here. In the last three months, insiders sold 111,140 shares of company stock worth $7,054,647. Insiders own 5.10% of the company’s stock.
IART has been the topic of a number of analyst reports. Zacks Investment Research cut Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Tuesday, June 26th. Citigroup cut Integra Lifesciences from a “buy” rating to a “neutral” rating and upped their price target for the company from $64.00 to $66.00 in a research report on Monday, July 2nd. BidaskClub cut Integra Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 12th. Oppenheimer reiterated a “buy” rating and issued a $74.00 price target on shares of Integra Lifesciences in a research report on Wednesday, July 25th. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $59.00 price target on shares of Integra Lifesciences in a research report on Wednesday, July 25th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the company’s stock. Integra Lifesciences has a consensus rating of “Hold” and an average target price of $62.15.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Further Reading: What are the reasons investors use put options?
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.